^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CS-1 inhibitor

    Related drugs:
    8d
    Elotuzumab enhances the anti-tumor activity of Vγ9Vδ2 T cells against Primary Effusion Lymphoma. (PubMed, Eur J Pharmacol)
    Elo treatment significantly increased γδ T cell cytotoxicity and degranulation, and these effects were prevented by Fc receptor blockade or by Fc-deficient Elo, indicating an antibody-dependent cellular cytotoxicity (ADCC) mechanism. Our findings demonstrate for the first time that Elo directly boosts γδ T cell anti-tumor activity against PEL, offering novel preclinical evidence for combining Elo with γδ T cell therapy as a potential treatment strategy for this intractable lymphoma.
    Journal
    |
    SLAMF7 (SLAM Family Member 7)
    |
    Empliciti (elotuzumab)
    14d
    SWOG-1211: S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=142, Completed, SWOG Cancer Research Network | Active, not recruiting --> Completed
    Trial completion
    |
    SKY92 Test
    |
    lenalidomide • bortezomib • Empliciti (elotuzumab) • dexamethasone injection
    27d
    CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov)
    P2, N=67, Completed, Bristol-Myers Squibb | Trial completion date: Nov 2025 --> Feb 2026 | Trial primary completion date: Nov 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • lenalidomide • bortezomib • dexamethasone • pomalidomide • Empliciti (elotuzumab)
    2ms
    IMPEDE: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Medical College of Wisconsin | Recruiting --> Active, not recruiting | N=53 --> 28 | Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Apr 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    pomalidomide • Sarclisa (isatuximab-irfc) • Empliciti (elotuzumab)
    2ms
    A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial primary completion date
    |
    lenalidomide • Hiltonol (poly-ICLC) • PVX-410 • citarinostat (ACY-241)
    2ms
    Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis. (PubMed, Ann Med)
    Elotuzumab in MM appears safe but with a specific adverse events pattern : lower neutropenia, but higher respiratory, gastrointestinal, metabolic, and infectious events. Differences may be influenced by longer treatment and corticosteroid use; therefore, interpretation of outcomes such as hyperglycemia and cataracts requires particular caution.
    Retrospective data • Journal • Adverse events
    |
    SLAMF7 (SLAM Family Member 7)
    |
    Empliciti (elotuzumab)
    2ms
    CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov)
    P2, N=67, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • lenalidomide • bortezomib • dexamethasone • pomalidomide • Empliciti (elotuzumab)
    3ms
    The Anti-SLAMF7 Antibody, Elotuzumab, Induces Antibody-Dependent Cellular Cytotoxicity Against CLL Cell Lines. (PubMed, Molecules)
    ADCC was assessed by flow cytometry using E (100 μg/mL), rituximab (R, 100 μg/mL), and their combination (E + R). The combination of E + R showed no significant synergy over monotherapies. In conclusion, elotuzumab induced significant ADCC in CLL cells, warranting further therapeutic evaluation.
    Preclinical • Journal • IO biomarker
    |
    SLAMF7 (SLAM Family Member 7)
    |
    Rituxan (rituximab) • Empliciti (elotuzumab)
    3ms
    Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies (clinicaltrials.gov)
    P1, N=27, Recruiting, Abdullah Khan | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon)
    |
    Empliciti (elotuzumab) • Hemady (dexamethasone tablets) • mezigdomide (CC-92480) • dexamethasone injection
    3ms
    A Multicentre Phase 3 Trial Comparing Elotuzumab-Cyclophosphamide-Thalidomide-Dexamethasone (E-CTD) with Cyclophosphamide-Thalidomide-Dexamethasone (CTD) for the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM) (ACTRN12616001030460)
    P3, N=300, Active, not recruiting, Australasian Leukaemia and Lymphoma Group (ALLG) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • thalidomide • Empliciti (elotuzumab)
    4ms
    A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    bortezomib • pomalidomide • Empliciti (elotuzumab)
    4ms
    Elo-KRd: Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov)
    P2, N=46, Completed, University of Chicago | Trial completion date: Mar 2027 --> Dec 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    lenalidomide • carfilzomib • dexamethasone • Empliciti (elotuzumab)